RxDoctor Payments Data

Eugene Parent, MD

Cardiovascular Disease · Bradenton, FLNPI 1437135621

Payments from drug & device makers

$301,619in general payments, 2019–2025

Across 629 payments — averaging $479.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$109K
  • Abbott$86K
  • Lilly USA, LLC$71K
  • Boston Scientific$30K
  • Edwards Lifesciences$1K
  • Medtronic$934
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$23,5008%
  • Speaking & faculty fees$243,43781%
  • Travel & lodging$17,4606%
  • Food & beverage$17,2046%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$301,619 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$494,926
Medicare patients
2,752
Services billed
7,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban506$586,907
JardianceEmpagliflozin155$207,041
XareltoRivaroxaban138$169,625
Repatha SureclickEvolocumab148$160,941
EntrestoSacubitril/Valsartan112$136,911
MultaqDronedarone Hcl79$124,770
Praluent PenAlirocumab39$39,571
Metoprolol Succinate660$9,226
LivaloPitavastatin Calcium16$7,636
Rosuvastatin Calcium516$6,959
Atorvastatin Calcium789$6,640
Valsartan264$6,361
Amiodarone Hcl119$4,414
Losartan Potassium380$4,181
ClopidogrelClopidogrel Bisulfate361$3,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$586,907506 claims
Boehringer IngelheimJardiance$108,940$207,041155 claims
Johnson & JohnsonXarelto$93$169,625138 claims
NovartisEntresto$221$136,911112 claims
Sanofi-aventis U.S. LLCMultaq$138$124,77079 claims
Kowa Pharmaceuticals America, Inc.Livalo$16$7,63616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →